5:01 PM
 | 
Apr 24, 2013
 |  BC Extra  |  Company News

BioMarin submits Vimizim MAA

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) submitted an MAA to EMA for Vimizim elosulfase alfa to treat mucopolysaccharidosis...

Read the full 70 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >